shutterstock_274590824

Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron

February 26, 2019
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma

Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …

neurons-3743011_960_720

Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding

February 26, 2019
Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d

Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …

lynparza

Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

February 26, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …

costa_rica

Unvaccinated French boy blamed for reintroducing measles to Costa Rica

February 26, 2019
Manufacturing and Production Costa Rica, France, WHO, vaccine hesitancy, vaccines

A French boy is suspected of reintroducing measles to Costa Rica after the country has been free of the infectious …

vaccination-1215279_960_720

Rise in populism linked to vaccine hesitancy in Europe, study shows

February 26, 2019
Manufacturing and Production EU, Europe, populism, populist parties, vaccine hesitancy, vaccines

Parent’s reluctance to vaccinate their children correlates with the number of people voting for populist parties, according to a study …

Living with melanoma after surgery

February 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma

Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …

shutterstock_168864905

Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals

February 25, 2019
Sales and Marketing Clementia pharmaceuticals, acquisition, ipsen, rare disease

In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with …

cocaine

UK launches drug testing service for illicit drugs

February 25, 2019
Sales and Marketing Home office, UK, cocaine, drugs, fentanyl, illicit substances, recreational drugs

The UK Home Office have licensed a drug-checking service for users of illicit substances. The yearlong pilot project, run by …

johnson_and_johnson_jj

Missouri Supreme Court ruling could help J&J in talc cases

February 25, 2019
Sales and Marketing Cancer, J&J, JJ, asbestos, baby powder, lawsuits, legal, talc

The Missouri Supreme Court has ruled that the practice of combining two or more cases in order to allow courts …

Roche set to acquire Spark Therapeutics in $4.8 billion deal

February 25, 2019
Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma

Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …

iran

Iran ready to export medicines to Venezuela

February 25, 2019
Sales and Marketing FDA, Iran, Venezuela, biotech, global, pharma

The chairman of the Iranian Food and Drug Administration (FDA) Mehdi Pirsalehi, has said that Iran is ready to export …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …

US Department of Justice investigate J&J over Baby Powder allegations

February 22, 2019
Medical Communications Cancer, J&J, JJ, Johnson and Johnson, USA, asbestos, oncology, talc

The Justice Department and US Securities and Exchanges Commission are investigation healthcare giant Johnson & Johnson over allegations that Johnson’s …

img_4190-e1376666350337-web

MHRA warns of congenital malformation risk of neo-mercazole during pregnancy

February 22, 2019
Medical Communications, Research and Development MHRA, neo-mercazole, pharma

UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) …

Genetically modified twins may have been altered in a way that improves memory and cognition

February 22, 2019
Medical Communications CCR5, HIV, cognitive enhancement, crispr, gene editing

The twins who were genetically modified using the gene editing tool CRISPR may have been changed in a way that …

Poison control calls for kratom increase from one a month to two a day, study shows

February 22, 2019
Medical Communications USA, herbal medicines, kratom, poison control, toxicology

The number of phone calls to US poison control centres over exposures to kratom – an herbal drug with opioid …

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

February 21, 2019
Research and Development Cancer, FDA, Xencor, leukaemia, pharma

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …

facilities_lg06

Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

February 21, 2019
Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

February 21, 2019
Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …

The Gateway to Local Adoption Series

Latest content